These T cells are modified to specifically recognize GBM antigens such as IL13Rα2, HER2, EphA2, and EGFRvIII, the first antigens to be tried in this type of immunotherapy [50,51], and phase I trials in humans are ongoing. Here, IL13RA2 is linked to glioblastoma.